Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

Aug 05 2016

• By Derrick Gingery

Related Content

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says

Apr 19 2016

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Jul 22 2016

Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?

Jul 10 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

Aug 05 2016

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Aug 05 2016

Related Companies

AbbVie Inc.

Amgen, Inc.

Novartis AG

Additional Topics

United States Biosimilars Drug Review Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window